Form 4: Wave Life Sciences Director Sells Shares Under 10b5-1 Plan

Wave Life Sciences Director Mark Corrigan sold 16,115 ordinary shares for approximately $220,000 through a pre-arranged trading plan.

Summary

• Mark Corrigan, a Director of Wave Life Sciences Ltd. (WVE), reported the sale of ordinary shares.
• The transactions occurred on December 8, 2025.
• A total of 16,115 ordinary shares were sold in two separate transactions.
• The first transaction involved 9,600 shares at a weighted-average price of $13.09 per share, with a price range of $12.75 to $13.69.
• The second transaction involved 6,515 shares at a weighted-average price of $14.065 per share, with a price range of $13.75 to $14.71.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted on August 6, 2025.
• Following these transactions, Mark Corrigan beneficially owns 28,815 ordinary shares directly.

Sentiment

Score: 4

Explanation: The sale of shares by a director, even if pre-arranged, can be viewed with slight caution by the market. However, the existence of a Rule 10b5-1 plan mitigates the negative sentiment as it indicates the decision to sell was made in advance of any material non-public information.

Negatives

• A director, Mark Corrigan, sold 16,115 ordinary shares of Wave Life Sciences Ltd.
• Insider selling, even if pre-arranged, can sometimes be perceived negatively by the market.

Future Outlook

NA

Industry Context

This filing reports a routine insider transaction by a director and does not provide information related to broader industry trends or competitive landscape.

Related Party Transactions

• Mark Corrigan, a Director of Wave Life Sciences Ltd., sold 16,115 ordinary shares of the company.

Stakeholder Impact

• Shareholders: May interpret the director's sale as a signal, though the 10b5-1 plan suggests it is not based on new negative information.

Key Dates

Recommendation

The filing reports a director's sale of shares under a pre-arranged 10b5-1 trading plan. While insider selling can sometimes be a bearish signal, the existence of a 10b5-1 plan suggests the decision to sell was made in advance and not necessarily based on new, negative material information. Without additional context on the company's financial performance, strategic outlook, or other insider trading patterns, this single transaction is not sufficient to change a fundamental investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Wave Life Sciences, WVE, Form 4, Insider Trading, Director Sale, Mark Corrigan, 10b5-1 Plan, Ordinary Shares